Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group (AU:MYX)
ASX:MYX
MYX Stock Chart & Stats
AU$6.01
-AU$0.13(-2.74%)
At close: 4:00 PM EST
AU$6.01
-AU$0.13(-2.74%)
Day’s Range― - ―
52-Week RangeAU$2.60 - AU$7.31
Previous CloseN/A
Volume149.18K
Average Volume (3M)593.75K
Market Cap
AU$214.49M
Enterprise ValueAU$196.73M
Total Cash (Recent Filing)AU$100.40M
Total Debt (Recent Filing)AU$41.27M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Feb 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding81,245,830
10 Day Avg. Volume776,050
30 Day Avg. Volume593,750
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside1.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stable Capital StructureA debt-to-equity ratio of 0.11 indicates low financial leverage, giving the company structural flexibility to fund operations, absorb revenue shocks, and invest in R&D or manufacturing without heavy interest burdens. This reduces refinancing risk over the medium term.
High Gross MarginA 60%+ gross margin reflects strong unit economics from manufacturing and a favorable product mix (branded/specialty and CDMO). If operating expenses are controlled and sales stabilize, this margin provides durable upside to restore operating profitability and sustain competitive pricing power.
Diversified Pharmaceutical Business ModelMultiple revenue streams—branded commercial products, generics and contract development/manufacturing—create structural resilience. Exposure to U.S. and Australian markets plus CDMO contracts offers repeatable fee income and pathways to scale higher-margin branded sales over time.
Bears Say
Declining Revenue And Persistent LossesSustained revenue decline and ongoing net losses erode scale and margin leverage, worsening unit economics and limiting ability to invest in product launches or commercial expansion. Over months, continued top-line contraction can force cost cuts that impair growth prospects.
Weak Cash Generation And ConversionSeverely negative FCF growth and very low cash conversion indicate the business struggles to turn earnings into cash. This creates durable liquidity pressure, constrains capex and working capital, and increases dependence on external financing for sustaining operations and CDMO commitments.
Negative Return On EquityA deeply negative ROE demonstrates the company is destroying shareholder capital rather than generating returns. Persistently negative ROE undermines investor confidence, makes equity raises dilutive and limits long-term funding options for commercial expansion or product development.
Mayne Pharma Group News
MYX FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest share price was AU$2.60 and its highest was AU$7.31 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is AU$214.49M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Feb 23, 2026 which is tomorrow.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Aug 28, 2025. The company reported -AU$0.841 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.847.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Undervalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of AU$0.544 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -AU$0.841 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went up 2.783%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in AU:MYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (1.50% Upside)
AU$6.10 (1.50% Upside)
Blogger Sentiment
Bullish
AU:MYX Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth AU$401.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-21.13%
Trailing 12-Months
Asset Growth
-12.91%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MYX Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(1.50% Upside)
Technical Analysis
Cogstate Ltd
―
Immutep Ltd
―
Dimerix Limited
―
Clarity Pharmaceuticals Ltd.
―
Cyclopharm Limited
―
Options Prices
Currently, No data available
---